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ABSTRACT 
Cyclooxygenase2 (COX2) has been associated with cell growth, invasiveness, 
tumor progression and metastasis of colorectal carcinomas. However, the downstream 
prostaglandin (PG)-PG receptor pathway involved in these effects is poorly 
characterized.
We studied the PG-pathway in gene expression databases and we found that 
PTGS2 (prostaglandin G/H synthase and cyclooxygenase) and PTGES (prostaglandin 
E synthase) are co-expressed in human colorectal tumors. Moreover, we detected 
that COX2 and microsomal Prostaglandin E2 synthase 1 (mPGES1) proteins are both 
up-regulated in colorectal human tumor biopsies.
Using colon carcinoma cell cultures we found that COX2 overexpression 
significantly increased mPGES1 mRNA and protein. This up-regulation was due to 
an increase in early growth response 1 (EGR1) levels and its transcriptional activity. 
EGR1 was induced by COX2-generated PGF2b. A PGF2b receptor antagonist, or EGR1 
silencing, inhibited the mPGES1 induction by COX2 overexpression. Moreover, 
using immunodeficient mice, we also demonstrated that both COX2- and mPGES1-
overexpressing carcinoma cells were more efficient forming tumors.
Our results describe for the first time the molecular pathway correlating PTGS2 
and PTGES in colon cancer progression. We demonstrated that in this pathway mPGES1 
is induced by COX2 overexpression, via autocrine PGs release, likely PGF2b, through 
an EGR1-dependent mechanism. This signaling provides a molecular explanation to 
PTGS2 and PTGES association and contribute to colon cancer advance, pointing out 
novel potential therapeutic targets in this oncological context.
INTRODUCTION
Colorectal cancer is the most common malignancy 
and the second most common cause of cancer death in 
Europe [1]. Even in patients who have undergone tumor 
resection, 40–50% relapse and die of metastases, being 
the overall 5-year survival less than 60% [2]. Thus, the 
currently available treatments do not achieve the desired 
efficiency and development of new therapeutic strategies 
is required.
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Clinical trials and epidemiological studies have 
suggested that cyclooxygenase 2 (COX2) is involved 
in colorectal cancer development and its inhibition can 
reduce the risk of cancer in general and more specifically 
of colorectal cancer [3–7].
The activity of cyclooxygenases (COX) is coupled 
to several terminal synthases that produce the different 
PGs [8]. The major PGs produced are the PGE2, PGD2, 
PGF2α, PGI2 by their respective synthases and are present 
in the healthy colon as well as in colorectal cancer [9]. 
PGE2 has been proposed as the principal prostanoid 
associated to colorectal tumors since PGE2 levels are 
elevated in patients with colon cancer and correlate 
with tumor size [10]. Three PGE2 synthases have been 
described [11], two microsomal, mPGES1, mPGES-2 and 
the cytoplasmic cPGES, encoded by the PTGES, PTGES2 
and PTGES3 genes, respectively. mPGES1 expression 
has been associated to colorectal cancer incidence and 
prognosis [12, 13] and has been proposed to cooperate 
with COX2 to enhance tumor growth [14].
Early growth response 1 (EGR1) is a transcriptional 
regulator that belongs to the EGR family of the 
C2H2-type zinc finger proteins. EGR1 is rapidly induced by 
a variety of stimuli, such as lipopolysaccharide, cytokines 
and growth factors, and regulates gene expression of 
proteins required for mitosis, inflammatory responses and 
differentiation [15]. It has been established that several 
prostanoids and more particularly PGF2α and PGE2 can 
induce EGR1 expression [16, 17]. EGR1 can also activate 
mPGES1 expression coordinately with NFκB or by itself 
in a variety of cell types [18–20]. Finally, EGR1 has been 
shown to induce apoptosis in cancer cells when up-regulated 
by NSAIDs [21, 22], thus the role of EGR1 is controversial.
In contrast to the wealth of data relating COX2 and 
colon cancer, there is little direct experimental evidence 
demonstrating that the expression/activity of COX2 or 
mPGES1 is causally linked to tumor progression and 
metastasis, in colorectal cancer. Besides, the PGs pathways 
downstream of COX2 mediating its pro-tumoral effects 
are mostly unknown. Thus, to further investigate the 
direct effects of the COX2/prostanoids pathway by itself 
in colorectal tumor progression, we generated stable colon 
carcinoma cell lines that overexpressed the human COX2 
gene. These cell lines have increased tumorigenic capacity 
both in vitro and in vivo and we found altered expression 
levels of various components of the PG pathway including 
mPGES1. Notably, we found co-localization of COX2 
and mPGES1 in human colorectal cancer biopsies and 
human tumor array data sets. Besides, overexpression of 
mPGES1 was enough to provide cells with an increased 
tumorigenic capacity in immunodeficient mouse xenograft 
models. This is the first report to demonstrate that high 
levels of any of the two enzymes are sufficient to enhance 
colorectal tumor growth and that COX2 activity induces 
mPGES1 expression through EGR1.
RESULTS
PGs pathway in colorectal cancer tumors
To study the implication of the COX-
prostaglandin(s)-PG receptor(s) genes in colorectal cancer, 
we collected information on their mRNA expression levels 
using the OncoMine database (http://www.oncomine 
.org; Compendia Bioscience, LifeTechnologies). These 
analyses showed that several members of this pathway 
are up-regulated in different human tumors (a summary is 
shown in Fig. 1A). Regarding colorectal tumors PTGS2, 
PTGES and PTGER3 were found up-regulated in many 
datasets. PTGS2, the gene that encodes for COX2 was 
significantly (p < 0.0001) up-regulated in 3 distinct 
datasets comparing tumor to normal tissue. Moreover, 
it was expressed at high levels in a subset of the tumor 
samples of the 21% of the collections (outlier analysis, 
as defined by Oncomine, expression profile analysis 
where high or low gene expression is seen in a fraction of 
samples of the total population/tumor collection without 
affecting significantly the average value of the population, 
but receives a high score from Oncomine’s algorithm). 
PTGES on the other hand, which encodes mPGES1, was 
found significantly increased in 3 analyses of colorectal 
cancer vs. normal tissue, as well as in 8 other cancer 
type datasets. After outlier analysis high expression was 
found in samples of the 13% of the collections. PTGS2 
and PTGES are both up-regulated in colorectal tumors 
when compared to normal tissue, while the PG receptor 
genes expression levels vary considerably, not correlating 
with the expression of PTGS2 and PTGES (not shown). 
We then analyzed whether the PTGS2 and PTGES are 
co-expressed/co-induced in cancer cells calculating the 
Pearson correlation coefficient of their gene expression 
values for each tumor sample. There is a very strong 
correlation between the two genes expression levels in two 
independent collections of colorectal tumor specimens, 
Skrzypczak Colorectal 2 and Gaedcke Colorectal, 0.836 
and 0.714, respectively (Fig. 1B). Similar results were 
obtained when we analyzed the data generated by the 
TCGA Research Network [29] (http://cancergenome.
nih.gov/) using the cBioportal for Cancer Genomics [30] 
(http://www.cbioportal.org/): PTGS2 and PTGES show 
a tendency towards co-occurrence (p < 0.001). On the 
other hand, cell-line gene expression analysis, using the 
Cancer Cell Line Encyclopedia [31] tools (http://www.
broadinstitute.org/ccle/home) also resulted in a strong 
correlation of the expression levels of the two genes 
(Pearson’s correlation = 0.45). All these in silico findings 
strongly support the coordinated involvement of the 
PTGS2-PTGES axis in colorectal cancer development. 
Moreover, we analyzed the mRNA levels of various cell 
lines to find a similar correlation between the levels of the 
two genes (Fig. 1C).
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Figure 1: PG Partway gene expression analysis in human tumors. A. Summary from the data obtained from the “Gene summary 
view” of the Oncomine database (Oncomine 2014, Compendia Bioscience) for each of the genes. The number of tumor collections where 
each gene was found significantly up- or down- regulated in tumor vs normal analyses is shown in the red and blue boxes respectively. In the 
pink and light-blue boxes are shown the number of collections that contain a subset of samples with very high or very low expression of the 
gene, respectively (outlier analysis). In parentheses, the number of colorectal cancer collections relative to the previously mentioned results 
are shown. B. Graphical representation of the PTGS2 and PTGES mRNA relative levels (as analyzed in the Oncomine database) dispersion, 
linear regression, and Pearson correlation coefficient. C. Graphical representation of the PTGS2 and PTGES ∆Ct (CtPTGS2 or PTGES – CtHPRT) 
dispersion, linear regression, and Pearson correlation coefficient, as calculated after qRT-PCR on RNA samples from the cell lines shown.
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mPGES1 and COX2 are co-expressed in human 
colorectal tumor biopsies
To confirm if COX2 and mPGES1 are co-expressed 
in human tumors, we tested by immunohistochemistry 
their expression in human colorectal tumor biopsies with 
different location, differentiation state, mucin expression 
and clinical stage. COX2 was expressed in most of the 
tumors tested, and almost always accompanied by mPGES1 
expression (Table 1 and Fig. 2). Thus, COX2 and mPGES1 
are co-expressed in human colorectal tumors as predicted in 
silico and found in colorectal cancer cell lines.
COX2 overexpression in colon adenocarcinoma 
cells results in PGs production and mPGES1 
increase
To address the mechanism mediating this coordinate 
expression, as well as its biological significance, 
we tested whether overexpression of COX2 enhances 
tumor progression and if this correlates with mPGES1 
up-regulation. For this, we generated several colon 
carcinoma cell lines, namely SW480ADH, Caco2, 
SW620, HT29 and HT29-lucD6, stably expressing COX2 
and compared them with control cells carrying the empty 
vector (EV), to avoid any possible artifact attributable to 
a single cell line. As expected, all COX2-overexpressing 
cell line expressed more PTGS2 mRNA, and COX2 
protein (not shown). For example, HT29-COX2 express 
9 fold more PTGS2 mRNA than the EV cells (Fig. 3A) 
and in HT29-lucD6-COX2, COX2 protein levels were 
higher than HT29-lucD6-EV control cells (Fig. 3B). This 
overexpression of COX2 resulted in much higher release 
(1.2 pg/ml/μg of protein for EV cells vs 14.1 pg/ml/μg 
of protein for COX2-overexpressing HT29 cells) of PGE2 
released to the supernatant (Fig. 3C) demonstrating that 
overexpressed COX2 is functional.
COX2-overexpression confers an enhanced  
pro-tumorigenic phenotype
PG production is associated to higher migration 
of colon tumor cells [25]. Thus, we next evaluated the 
effect of COX2 overexpression on cell migration. For 
this, Boyden chamber assays were performed for the 
HT29, Caco2 and SW480ADH -EV and -COX2 cell 
lines. In all cases COX2-overexpressing cells showed a 
significant tendency (p < 0.05, n = 3 for each cell line) to 
migrate more than the EV cells. For the HT29 cell line, an 
average of 20 ± 3 EV and 29 ± 4 COX2-overexpressing 
cells migrated in 48 h. This comparison resulted in 28 ± 
4 EV and 69 ± 6 COX2-overexpressing Caco2 cells and 
24 ± 3 EV and 33 ± 5 COX2-overexpressing SW480ADH 
cells. Migration was strongly increased when cells were 
pretreated with PMA Interestingly, in all the cases, COX2-
overexpressing cells migrated significantly more than their 
EV counterparts (Fig. 3D–3E). PMA treatment did not 
affect COX2 protein levels (not shown).
We next sought to test if COX2 overexpression 
favored tumor growth in vivo. HT29-COX2 cells produced 
larger tumors than the EV cells in the nude mice xenograft 
cancer progression model (Fig. 4A). Similar experiments 
were performed in SCID mice using the HT29-lucD6 
derivatives and evolution of the tumors was monitored by 
bioluminescence. Again, COX2-overexpressing cells grew 
faster than the EV cells (Fig. 4B and 4C). These results 
indicate that COX2 overexpression promoted faster tumor 
growth in vivo.
Moreover, we were able to detect metastatic tumors 
21 days after the surgical removal of primary HT29-lucD6-
EV cells derived tumor in a minor fraction of the mice 
(17%). On the contrary, in mice inoculated with HT29-
lucD6-COX2 cells we detected metastasis were detected 
earlier and 5 weeks post inoculation half of the animals had 
metastasis (Fig. 4D). All metastases occurred in the lung 
and were always found near a blood vessel (not shown). 
This supports the role of COX2 in favoring lung metastasis 
as it has been reported for mammary tumors [5, 32, 33].
COX2 overexpression induces PTGES 
through EGR1
Interestingly, we found that mPGES1 was 
significantly up-regulated in all COX2-overexpressing 
colorectal carcinoma cell lines tested (an example of HT29 
and SW480ADH is shown in Fig. 5A and for Caco2-COX2 
a 14 ± 3 fold increase of PTGES was observed when 
comparing to EV cells). This gene induction by COX2 
overexpression is specific to PTGES since the levels of 
other components of the PG pathway, such as PTGES2, 
PTGES3 or PGFS remained unchanged (Fig. 5B). More 
interestingly, in vivo subcutaneous tumors in nude mice 
express higher levels of mPGES1 when they originate 
from COX2-overexpressing cells (Fig. 5C). Additionally, 
we analyzed mRNA levels of several components of the 
COX-PG synthases-PG receptors pathway both in vitro, in 
cells in culture, as in vivo, in the tumors extracted from the 
nude mice to find a 2-fold increase of PTGES levels in the 
COX2 tumors (Fig. 6). These data confirmed that COX2 
overexpression in colon carcinoma cells concomitantly 
leads to the up-regulation of mPGES1-PGE2 pathway. 
Interestingly, PTGS2 expression was increased in control 
HT29-EV xenotransplanted cells derived tumors as 
compared to the levels of these cells in culture. This may 
explain the lower differences between the lines found 
in vivo.
Next, we studied the molecular mechanisms 
responsible for mPGES1 up-regulation. Inhibition of COX2 
enzymatic activity with Aspirin or Etoricoxib reverted 
the induction of mPGES1- in COX2-overexpressing 
cells (Fig. 7A), confirming that it was due to enhanced 
COX2 activity in those cells. We then examined the 
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Table 1: Expression of mPGES1 and COX2 in human tumor samples and clinical characteristics of 
the human tumors analyzed (Location, Differentiation state Mucin expression and clinical stage)
BIOPSY 
NUMBER
Location Differentiation 
state
Mucinous Stage COX2 staining mPGES-1 
staining
1 Rectum/sigmoid moderate no PT3N2M0 ++ ++
2 Cecum well no T3N1Mx + ++
3 Rectum well no NA ++ ++
4 Rectum well no uT3uN2M1 - +++
5 Ascending well yes T3N2M1 ++ ++
6 Rectum/sigmoid well yes PT3N2Mx + +
7 Cecum well no PT3N2bMx ++ ++
8 Transverse moderate no Pt3n0m0 Immune cells. No tumor cells ++
9 Transverse/right well no PT4N0Mx ++ +++
10 Transverse moderate no PT3N0M0 + ++
11 Transverse moderate no PT3N0M0 ++ +++
Figure 2: COX2 and mPGES1 expression in human colorectal tumor biopsies. Samples from colorectal tumors were processed 
for immunohistochemistry using antibodies specific for COX2 and mPGES1. Magnification 200 ×.
Oncotarget39946www.impactjournals.com/oncotarget
Figure 3: COX2 overexpression enhances cell migration. A. Relative levels of PTGES mRNA in the EV and COX2 HT29 cells 
as estimated by qRT-PCR. B. WBs for COX2 and HSP90 protein levels of the HT29-LucD6-EV and COX2. C. Relative PGE2 levels of the 
HT29-EV and COX2 cells supernatants after ELISA quantification. D. Cell counts of Boyden chamber migration assays towards serum of 
the indicated cells stimulated or not with PMA. E. Representative images are shown. Magnification 50 ×.
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COX2-derived prostanoid(s) involved in the up-regulation 
of mPGES1. PGE2 treatment of HT29 cells did not affect 
PTGES mRNA levels (not shown) while PGF2α caused a 
6-fold increase (Fig. 7B). Besides, treatment with PGF2α 
receptor (FP) antagonist AL8810 significantly reduced the 
PTGES mRNA induction in COX2-overexpressing cells, 
indicating a COX2/PGF2α dependent induction. Similar 
results were obtained in SW480ADH cells (not shown). To 
identify the signaling pathways involved, we transfected 
the EV and the COX2 HT29 cells with luciferase reporter 
constructs containing the “full length” PTGES promoter, 
construct A (−631 to − 1 bp), or just the proximal promoter 
region, construct B (−177 to − 1 bp) [27] as shown in 
Fig. 7C. Luciferase activity was high when any of the two 
constructs were transfected in the COX2-overexpressing 
cells (Fig. 7D). This confirms that COX2 activates the 
PTGES promoter and indicates that the transcription factor 
binding sites responsible for this PTGES transcriptional 
up-regulation are localized in the proximal promoter region, 
where three EGR1 response elements have been identified 
[19]. Similar results were obtained with SW480ADH 
and Caco2 cells (not shown). In agreement with these 
results, we found that EGR1 mRNA is up-regulated in 
COX2-overexpressing cells and that an EGR1-reporter 
construct was more active in COX2-overexpressing cells 
(Fig. 7E and 7F). Similar results were obtained in Caco2 
cells (not shown). Conversely, PGF2α treatment increased 
2-fold this reporter construct activity in SW480ADH (±0.1) 
and HT29 (2.2 ± 0.3) cells. Additionally, we tested what 
PGs were able to induce EGR1 in different colorectal 
cancer cell lines (Fig. 7G for mRNA and 7H for protein). 
Finally, EGR1 overexpression caused a great increase in 
PTGES mRNA in HT29 (14.26 ± 2.15, p < 0.01) and Caco2 
Figure 4: COX2 overexpression increases tumor growth capacity and metastasis of HT29 cells in nude and SCID 
mice. A. Growth of HT29-EV and HT29-COX2 subcutaneous tumors in nude mice (10 mice per group). Tumor size (±SEM) 5 weeks 
post-injection. B. Growth of HT29-lucD6-EV and -COX2 subcutaneous tumors in SCID mice (5 mice each). Growth was evaluated by 
light emission of the cells after D-Luciferin injection. C. Representative images of animals carrying the mentioned tumors, pseudocolored 
according to bioluminescence intensity. D. Percentage of mice with metastasis detected by bioluminescence after removal of the primary 
tumor.
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cells (8.3 ± 2.9, p < 0.05), supporting the direct regulation 
of PTGES expression by EGR1.
To further confirm this, we tested whether RNA 
interference for EGR1 would reduce the expression 
levels of PTGES. As it can be observed in Fig. 8 (upper 
panel), EGR1 knockdown reduced the PTGES mRNA 
levels in COX2-overexpressing HT29 cells without 
affecting PTGS2 levels (similar results were obtained 
in SW480ADH cells, not shown). Besides, EGR1 
knockdown also reduced mPGES1 protein levels induced 
Figure 5: COX2 overexpression induces mPGES1 up-regulation. A. PTGES mRNA levels are higher in HT29-LucD6 
or SW480ADH cells overexpressing COX2 comparing to EV cells, as estimated by qRT-PCR. B. mRNA levels of different genes 
encoding for key enzymes of the prostanoid biosynthesis pathway in HT29-EV and COX2 cells. No significant differences were found. 
C. Immunohistochemistry for mPGES1 on tumor samples generated after subcutaneous injection of the cells, showed that COX2 tumors 
express 2–3 fold more mPGES1 than the EV ones. Magnification 200 ×.
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by COX2 as shown by immunofluorescence (Fig. 8, lower 
panels and graph). Although EGR1 knockdown does not 
significantly affect neither EGR1 nor mPGES1 levels in 
EV cells, probably due to their already low EGR1 levels, 
it prevents the up-regulation of EGR1 and mPGES1 in 
COX2-overexpressing cells. This was observed both at the 
mRNA and protein level. Furthermore, strong correlations 
of PTGS2 or PTGES and EGR1 mRNA levels in several 
cancer datasets were found, and particularly in Skrzypczak 
Colorectal 2 dataset, Pearson’s correlation was 0.84 for 
PTGS2 and EGR1 and 0.647 for PTGES and EGR1 mRNA 
levels (Table 2). Altogether these results demonstrate 
that mPGES1 is induced by COX2 overexpression, 
via autocrine PGs release, likely PGF2α, through an 
EGR1-dependent mechanism.
mPGES1 overexpression promotes tumor 
growth in vivo
The above results suggested that mPGES1 induction 
is a key point in the pro-tumorigenic activity of COX2. 
To confirm this we generated a HT29-lucD6 cell line 
Figure 6: The Cyclooxygenases-PGE2 pathway gene expression analysis after COX2 overexpression. Expression of PG 
pathway genes in vitro, in cells in culture, in vivo, in the tumors extracted from nude mice. Summary from the gene expression data obtained 
by qRT-PCR for each of the genes of the pathway analyzed, averages of three independent experiments in culture and for the tumors of 
4 mice are shown. -: undetectable. *the mRNA levels of these genes were found induced in the EV cells derived tumors as compared to the 
levels of the EV cells in culture.
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Figure 7: Regulation of mPGES1 expression by COX2 and EGR1. A. mPGES1 expression is reduced by aspirin (ASP, 1 μM) 
or etoricoxib (ETOR, 1 μM) treatment for 24 h, in both HT29-LucD6 EV and COX2 cells as quantified by qRT-PCR. B. PTGES mRNA 
is increased by PGF
2α
 (1 μM) in EV cells while it is reduced by AL8810 (10 μM) treatment (24 h) in HT29-LucD6-COX2. C, D. Relative 
luciferase activity of cells transfected with the “full length” (PTGES-A, -631 to -1) and “proximal” (PTGES-B, -177 to-1) constructs of 
the human PTGES promoter transfected in HT29-EV and –COX2 cells. E. mRNA levels of EGR1 were quantified by RT-PCR in samples 
from EV and COX2-overexpressing HT29-LucD6 and SW620 cells. F. Relative luciferase activity of an EGR1 reporter construct EV and 
COX2 in HT29 and SW480ADH cells. EGR1 mRNA G. and protein H. induction after 24 h treatment of the indicated cell lines with 1 μM 
of the PGs shown. *p < 0,005
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Figure 8: EGR1 silencing reduces the mPGES1 up-regulation by COX2. A. Relative levels of PTGS2, EGR1 and PTGES 
mRNA, estimated by RT-PCR analysis of HT29-EV and –COX2 cells transfected with 3 different shRNA expressing plasmids, 
specific for EGR1 or one shRNA without any known mammalian target (scr) . B. Immunofluorescence for mPGES1 and EGR1 of HT29-EV 
and –COX2 cells transfected as mentioned above. C. Fluorescence quantification averages of the images of three independed experiments, 
as in (B) *p < 0,001. Bar: 32 μm.
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carrying the PTGES gene, expressing more than 500-fold 
higher mRNA levels and confirmed the overexpression of 
the protein (Fig. 9A). mPGES1 overexpression was not 
as effective as COX2 to increase the total PG levels but 
increased the proportion of PGE2 in the total PGs while it 
reduced the proportion of PGF2α (Fig. 9B).
We then compared the in vivo tumorigenic activity 
of both mPGES1 and COX2 expressing lines in mouse 
xenograft experiments. As shown in Fig. 9C, COX2 tumors 
grew faster than the EV ones, as expected. Interestingly, 
the mPGES1-overexpressing cells formed tumors much 
faster that grew larger than the other two groups, with much 
higher bioluminescence signal, indicating higher numbers 
of living cells. Histological observations of the tumors 
showed more necrotic regions in the ones derived from the 
control cell line. Remarkably, the mPGES1 tumors were less 
compact, with less stroma, composed mainly of mucinous 
cells indicating higher degree of cell differentiation into the 
tumor. Immunohistochemical staining of the sections with 
an mPGES1 antibody showed stronger staining in HT29-
COX2 derived tumors than in the HT29-EV generated 
tumors and as expected very strong staining in the HT29-
mPGES1 tumors (Fig. 9D). This staining was specifically 
localized in the tumor cells, while no staining was observed 
for other cell types like immunologic infiltrate or stroma.
DISCUSSION
Epidemiological studies as well as experimental 
models have long suggested that COX2 plays an 
important role in colorectal tumorigenesis [6, 7, 34–36]. 
However, despite the wealth of data on COX2 and cancer, 
very few direct evidence of COX2 overexpression in 
colon carcinoma cells with tumor properties in vivo 
have been published. More importantly, no studies 
have comprehensively addressed the downstream PGs/
PG receptors pathways involved. Several studies have 
attributed COX2 effects to PGE2. Not withstanding this, 
the 2 published reports on the effect of genetic deletion 
of mPGES1 in mice on colon cancer are contradictory 
indicating that the mPGES1 deficient mice have either 
reduced [37] or accelerated [38] intestinal tumorigenesis, 
probably due to differences in the inflammatory responses.
Thus, we studied the possible downstream COX2 
effectors, as PG synthases-PG receptors, both in human 
colorectal cancer samples and in animal models. Data 
analysis from numerous collections of human tumors 
indicated that PTGS2 and PTGES expression correlated 
strongly, while for the rest of the members of the 
mentioned pathway we did not find any correlation. 
Importantly, we confirmed the in silico results in human 
colorectal tumor biopsies, being the first evidence of 
a relationship between COX2 activity and mPGES1 
expression levels in the same tumor settings.
To address the mechanism and consequences of this 
association, we overexpressed COX2 in several human 
carcinoma cell lines. Our results agree with previous 
work from our group and other groups, which have 
reported enhanced cell migration in cells with spontaneous 
up-regulation of COX2 and in cells that overexpress 
COX2 [25, 39–42]. Besides, we report for the first time 
that COX2 overexpression alone increased tumor growth 
and the number of metastases in mice, confirming that the 
overexpression of COX2 plays an important role in colon 
cancer progression and dissemination.
The tumorigenic effects of COX2 are considered 
to be due to the production of PGs [43], particularly 
PGE2 [44, 45]. The PGE2 synthase mPGES1, has been 
associated with carcinogenesis and proposed as marker 
of poor prognosis [13, 14, 46]. Both PTGS2 and PTGES 
genes share a similar transcriptional regulation by certain 
growth factors and pro-inflammatory stimuli [28, 47, 
48]. However, the possible link between these enzymes 
in colon cancer was not addressed before.
Interestingly, we found that COX2 overexpression 
caused the up-regulation of mPGES1 thus leading to 
increased PGE2 and PGF2α synthesis. We were able to 
demonstrate that this up-regulation depended directly 
on COX2 activity using specific and non-specific COX2 
inhibitors. Interestingly, mPGES1 induction depends, at 
least partially, on PGF2α, since an FP antagonist, AL8810, 
could revert it, giving a previously unrecognized role of 
this PG/FP in colon cancer. AL8810 is a PGF2α receptor 
antagonist that would only avoid activation of the receptor 
by newly synthetized PGF2α. However, this compound has 
itself a low level intrinsic capacity to activate the receptor, 
thus allowing low level induction of EGR1 and mPGES1. 
On the other hand, PGE2 is also able to induce EGR1 in 
certain circumstances and cell lines, thus the contribution 
of both PGs to the observed effect cannot be discarded. In 
this regard, it is well established that both PGF2α and PGE2 
can induce  EGR1 [16, 17]. Further studies are necessary 
to evaluate the effect of PGF2α on tumor progression and 
metastasis.
Using the PTGES promoter reporter constructs 
we confirmed the EGR1 and discarded NF-kB or CREB 
Table 2: Pearson’s correlation coefficient calculated from the gene expression data for the genes shown 
in the two colorectal tumor collections (Gaedcke colorectal and Skrzypczak Colorectal 2; Oncomine)
PTGES vs PTGS2 PTGES vs EGR1 PTGS2 vs EGR1
Skrzypczak Colorectal 2 0.836 0.647 0.840
Gaedcke Colorectal 0.714 0.408 0.235
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activation since the binding sites identified for these factors 
are present in the “full length” but not in the “proximal 
promoter” construct. EGR1, a transcription factor known 
to be important for the transcriptional regulation of PTGES 
in other cell types [19, 28] is responsible for the induction 
of mPGES1 by COX2. More importantly, silencing EGR1 
gene with RNA interference abrogated COX2-mediated 
PTGES induction proving a direct implication of EGR1 in 
this process. Supporting these results, data obtained from 
in silico analysis of tumor microarray gene expression 
levels show a strong correlation between the expression 
levels of the three genes, in colorectal tumors. Our results 
are also in agreement with reports of EGR1 down-
regulation by NSAIDs [27, 49] and up-regulation by PGE2 
Figure 9: mPGES1 overexpression in colon cancer cells. A. UP: mRNA levels of PTGES in control or mPGES1 overexpressing 
cells as estimated by qRT-PCR. DOWN: WB against mPGES1 and HSP90 in samples of the above mentioned cells. B. PGE2, PGF2α and 
total PG levels in supernatants of EV, COX2 and mPGES1 transduced HT29-Luc-D6 cells, quantified by ELISA immunoassay. The graph 
shows means and standard error of three independent experiments. C. Quantification of tumor produced bioluminescence of HT29-LucD6-
EV, -COX2 and –mPGES1 cells inoculated subcutaneously in nude mice (5 per group). One Nude mouse had developed metastasis before 
week 9 post injection in the axillar lymph node (shown in the lower part). D. At the end of the experiment mice were sacrificed, tumors were 
extracted and processed for immunohistochemistry using antibodies specific for COX2 and mPGES1. Magnification 200 ×.
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[50]. Besides, there are some reports implicating EGR1 
in colorectal and gastric cancer cell proliferation and 
metastasis [51, 52]. Moreover, EGR1 has been proposed to 
be one of the genes with increased expression early in the 
development of colorectal cancer [53] and to be implicated 
in stem cell marker regulation [54].
We also found that mPGES1-overexpressing colon 
carcinoma lines grow tumors faster, even faster than the 
COX2-overexpressing ones, indicating that mPGES1 
activity alone would be sufficient to promote tumor 
growth. In vitro, mPGES1 overexpression increases PGE2 
levels by taking advantage of the basal PGH2 production, 
conversely reducing the levels of other PGs like PGF2α. 
The change of the balance between the different PGs 
towards PGE2 may be enough to stimulate faster tumor 
growth.
In conclusion, we found here that COX2 
overexpression confers a more aggressive tumor 
phenotype in colon carcinoma cells and that this phenotype 
can be mimicked by mPGES1 overexpression. Besides, 
COX2 overexpression was functionally and casually 
linked to mPGES1 in human tumor samples and in all cell 
lines tested in vitro and in vivo derived tumors. Finally, 
our results unraveled a new molecular mechanism for this 
association involving COX2*PGF2a*EGR1*mPGES1 
that likely makes the sustained expression of COX2 the 
principal event necessary for tumor promotion by this 
cascade.
MATERIALS AND METHODS
Cell lines
The Caco-2, HCT116, SW620 and HT29 cell lines 
were obtained from the ATCC (LGC Standards, Barcelona, 
Spain). HT29-lucD6, stably expressing Firefly Luciferase, 
obtained from Caliper Life Sciences. The SW480ADH 
and SW480R cells [23] were a kind gift from Dr. Alberto 
Muñoz, Madrid, Spain. The Caco2 and HCT116 cells were 
obtained from the Centro de Investigaciones Biológicas 
Tissue culture Repository (Madrid, Spain). Cell lines were 
validated with the StemElite ID system (Promega). Cells 
were grown as described [24, 25].
The COX2-overexpressing cell lines and the empty 
vector controls (EV) were generated by transfection with 
the pBABE-puro vector carrying or not the human COX2 
gene, using Lipofectamine 2000 (Life Technologies) 
according to the instructions of the manufacturer. Cells 
were selected for one week with 2 μg/ml puromycin and 
then several independent mass cultures were obtained. 
COX2- and mPGES1-overexpressing cell lines were also 
generated by transduction with lentiviral particles carrying 
the mentioned genes or the empty vector, after subcloning 
to the pSMPUW-IRES-Bsd (Cell Biolabs) following the 
manufacturer’s instructions. Cells were grown under 
blasticidin (Invivogen) selection (4 μg/ml).
Aspirin and phorbol myristate acetate (PMA) were 
acquired from Sigma-Aldrich. Etoricoxib, from Merck 
Sharp & Dohme. AL8810, PGE2 and PGF2α were from 
Cayman Chemicals.
Tumor growth in immunodeficient mice
We used three strains of immunodeficient mice, 
Swiss Nude (Crl:NU(Ico)-Foxn1nu, Charles River 
Laboratory) and SCID (BALB/cJHan Hsd-Prkdcscid) or 
NOD-SCID (NOD.CB17-Prkdcscid/NCrHsd) from Harlan 
Laboratory. In the experiments with nude and NOD-SCID 
mice, groups of 4–6 animals were injected with 0.5× or 
3 × 106 cells from generated cell lines. For the SCID mice 
experiments, groups of 10 animals were injected with 
3 × 106 HT29-lucD6-COX2 or HT29-lucD6-EV cells 
in each flank of the back. Tumor volume was estimated 
with calipers by the following calculation: ([width]2 
× [length])/2. For HT29-LucD6 cell lines, bioluminescence 
acquisition on anesthetized mice (isofluorane gas, 1.5%, 
Abbott, Madrid, Spain) was performed using an IVIS 
Lumina II (Caliper Life Sciences) after intraperitoneal 
injection of 150 mg/kg of body weight of D-Luciferin 
(Promega). The luminescent signal was quantified with 
Living Image 3.2 software and expressed as photons/s 
(Average radiance). The animal experimentation complied 
with National and European Union legislation and was 
supervised by the center’s Ethics Committee.
Histological analysis and immunohistochemistry
Tumors from mice were fixed in 4% phosphate-
buffered formalin (pH 7.4), and 3 μm paraffin-embedded 
sections were stained with hematoxylin-eosin or 
immunostained as described previously [26]. Antibodies 
used for immunohistochemistry: anti-COX2 (Sigma-
Aldrich) or anti-mPGES1 (Cayman Chemicals Europe) 
and secondary antibody conjugated with HRP (Envision + 
Dual link System HRP, Dako). Finally, sections were 
developed using DAB solution (Liquid DAB + substrate 
chromogen system, DAKO K3468), counterstained 
with hematoxylin and images were taken with a 
LEICA DMD108 Digital Microimaging Device (Leica 
Microsystems). Human tumor biopsies were obtained after 
the approval of the Ramon y Cajal University Hospital 
Ethics Committee according to Spanish and EU laws.
In vitro cell migration assay
Migration assays were carried out basically as 
described [25]. Briefly, 2 × 104 cells were placed in 8 μm 
pore size transwell filter chambers in MEM without 
serum, prior 0.5 h treatment with PMA, 100 nM. The 
inserts were placed in wells filled with MEM 20% FBS. 
After 48 h at 37°C, they were processed and quantified as 
described [25].
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mRNA extraction and quantitative 
real time PCR
Total RNA was prepared from colon carcinoma cell 
lines by the TRIzol reagent (Invitrogen, Alcobendas, Spain) 
according to the manufacturer’s instructions. Total RNA was 
reverse transcribed into cDNA and the quantitative PCR 
was performed using the GoTaq 2-Step RT-PCR system 
(Promega). Relative mRNA levels to the housekeeping HPRT 
gene and to the experimental control point were calculated 
using the 2-∆∆CT formula from the values obtained. A list of the 
gene specific primers used can be found in Table 3.
Prostaglandin quantification
PGE2, PGF2α and total PGs were quantified using 
ELISA kits from Cayman Chemicals Europe, following 
the manufacturer’s instructions. The quantifications were 
performed on serum free medium incubated with cells 
during 4 hours at 37°C.
Table 3: Oligonucleotide primers used in this study
Gene Primer Sequence
HPRT CTGGAAAGAATGTCTTGATTGTGG
CATCTTTGGATTATACTGCCTGAC
PTGS1 GAAACCCTACACCTCCTTCC
GCATCAATGTCTCCATACAATTCC
PTGS2 CGAGGTGTATGTATGAGTGTG
GTGTTTGGAGTGGGTTTCAG
PTGES CTGGTCATCAAGATGTACGTG
GGGTAGATGGTCTCCATGTC
PTGES2 TCGCAACAACTAAATGACTCC
CTGGGTAGTAGGTGATGATCTC
PTGES3 AGAAAGGGCAAAGCTTAATTGG
ATCATCTGCTCCATCTACTTCTG
HPGD GCAGTTTGAACCTCAGAAGAC
CACTCCAGCATTATTGACCA
PHDS GCATGACGGAACAATAGGAC
GAACAGAGCAGAGACATCCA
HPGDS GGGAGAGCAGAAATTATTCGT
AGAGTAAGTCCATCAACTTCCA
PGFS (AKR1C3) TTCTCCAATGTCTCTAAAGCCA
ATCCTGCATCCTTACACTTCTC
PGIS AGAAATCTACACAGACCCAGAG
TGTAATTCTTCAGCCGTTTCC
PTGER1 GTCGGTATCATGGTGGTGTC
CGCAGTAGGATGTACACCCA
PTGER2 GTCTGCTCCTTGCCTTTCAC
TGAACGCATTAGTCTCAGAACAG
PTGER3 TCAACCTTGATGTGGAGCGA
GCAAATTCAGGGAAGCAGGA
PTGER4 TCTTACTCATTGCCACCTCCC
GTTGACGAATACTCGCACCAC
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Luciferase reporter assays
Cells were transfected with luciferase reporter 
constructs, namely PTGES-A-Luc, PTGES-B-Luc [27] 
or EGR1-pro36-Luc [28] together with the SV40-Renilla 
plasmid at a 80:1 proportion, with Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. 
6 h after transfection, media were replaced and 48 h later 
cells were lysed and processed using the Dual Luciferase 
Assay kit (Promega) and bioluminescence was measured 
in a Sirius manual luminometer (Berthold Detection 
Systems).
RNA interference
For stable RNA interference, the following Mission 
shRNA lentiviral vector constructs (Sigma Aldrich) 
were used: TRCN0000273910, TRCN0000013836, 
TRCN0000013833. Viruses were produced and 
cells were transduced following the manufacturer’s 
instructions. For transient knockdown, these constructs 
were transfected with Metafectene (Biontex Laboratories, 
GmbH) following the manufacturer’s instructions. 
Knowdown efficiency was evaluated by RT-PCR and 
immunofluorescence.
Western blot analysis
Western blots (WB) were carried out as described 
previously [24]. Membranes were incubated with specific 
antibodies against COX2, mPGES1 (Cayman Chemicals 
Europe) or anti-EGR1 (sc-189) or anti-HSP90 (sc-7947) 
antibody (Santa Cruz Biotechnology).
Immunofluorescence
Cells were plated on 12 mm diameter cristal 
coverslips the day after transfection. 48 h later cells were 
washed with PBS and fixed with 4% paraformaldehyde 
in PBS for 20 min. Cells were permeabilized with 0.1% 
Triton X-100 for 20 min and blocked with 2% BSA in 
PBS for 1 h. Antibody incubations were done in 1% BSA 
in PBS. Anti-mouse and anti-rabbit secondary antibodies 
(Alexa 488 and 555) were from Life Technologies. Images 
were acquires with a LSM510 laser confocal microscope 
(Zeiss) all in the same conditions and fluorescence 
intensity was calculated with the Fiji software (adapted 
version of Image J).
Statistical analysis
Results are expressed as means ± SEM. The 
Student’s t test were used for comparisons. *p < 0.05 and 
**p < 0.01 denote statistical significance. The statistical 
analysis was performed using the GraphPad Prism 
4.0 statistical software.
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